Trials / Unknown
UnknownNCT00069511
12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (planned)
- Sponsor
- United Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center study. Neither the study subjects nor the physicians will know what treatment an individual subject is receiving. Subjects will be randomly assigned (like flipping a coin) to one of five treatment groups. The treatment groups include four different dosing groups of active study drug and one group of subjects who will receive placebo. A 12 week follow up period occurs after the 12 weeks of dosing. The study endpoint is a reduction in Hepatitis C viral load.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UT-231B |
Timeline
- Start date
- 2003-07-01
- Completion
- 2004-12-01
- First posted
- 2003-09-30
- Last updated
- 2005-06-24
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00069511. Inclusion in this directory is not an endorsement.